These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28941707)

  • 1. Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation.
    Caminati M; Gatti D; Dama A; Lorenzetti L; Senna G
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):460-462. PubMed ID: 28941707
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma.
    Nagasaki T; Matsumoto H; Kanemitsu Y; Izuhara K; Tohda Y; Horiguchi T; Kita H; Tomii K; Fujimura M; Yokoyama A; Nakano Y; Hozawa S; Ito I; Oguma T; Izuhara Y; Tajiri T; Iwata T; Ono J; Ohta S; Yokoyama T; Niimi A; Mishima M
    Am J Respir Crit Care Med; 2014 Dec; 190(12):1449-52. PubMed ID: 25496105
    [No Abstract]   [Full Text] [Related]  

  • 5. High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study.
    Morimoto C; Matsumoto H; Tajiri T; Gon Y; Ito R; Hashimoto S; Suzukawa M; Ohta K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Kanemitsu Y; Nagasaki T; Izuhara Y; Niimi A; Hirai T
    J Asthma; 2021 Sep; 58(9):1133-1142. PubMed ID: 32375555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Ricci A; Cresti A; Santus P; Olivieri C; Perrella A; Rogliani P; Paggiaro P;
    J Allergy Clin Immunol Pract; 2019; 7(5):1643-1646. PubMed ID: 30898690
    [No Abstract]   [Full Text] [Related]  

  • 7. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?
    Amat F; Labbé A
    Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
    Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
    Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
    Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
    Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Therapy in a Patient with Asthma and Nasal Polyps.
    Caminati M; Senna G
    J Allergy Clin Immunol Pract; 2019; 7(5):1700-1701. PubMed ID: 31076065
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
    Clavenna MJ; Turner JH; Samuelson M; Tanner SB; Duncavage J; Chandra RK
    Allergy Asthma Proc; 2016; 37(1):23-6. PubMed ID: 26831843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
    Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
    J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of a multidomain assessment of steroid response for predicting clinical response to omalizumab.
    Fleming L; Koo M; Bossley CJ; Nagakumar P; Bush A; Saglani S
    J Allergy Clin Immunol; 2016 Jul; 138(1):292-294. PubMed ID: 26924468
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab management beyond clinical trials: the added value of a network model.
    Caminati M; Senna G; Chieco Bianchi F; Marchi MR; Vianello A; Micheletto C; Pomari C; Tognella S; Savoia F; Mirisola V; Rossi A;
    Pulm Pharmacol Ther; 2014 Oct; 29(1):74-9. PubMed ID: 24508951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids.
    Zeiger RS; Schatz M; Zhang F; Crawford WW; Kaplan MS; Roth RM; Chen W
    J Asthma; 2011 Feb; 48(1):8-17. PubMed ID: 21155706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.